ASX - By Stock
|
MSB |
Re:
Ann: FDA Grants Orphan Drug Designation for Revascor
|
|
mtom
|
241 |
81K |
3 |
19/02/24 |
19/02/24 |
ASX - By Stock
|
241
|
81K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on Institutional Placement and Entitlement Offer
|
|
mtom
|
512 |
122K |
9 |
03/01/24 |
03/01/24 |
ASX - By Stock
|
512
|
122K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
The Psychology of Trading
|
|
mtom
|
893 |
273K |
4 |
29/07/23 |
29/07/23 |
ASX - By Stock
|
893
|
273K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
mtom
|
4.8K |
2.3M |
9 |
28/07/23 |
28/07/23 |
ASX - By Stock
|
4.8K
|
2.3M
|
9
|
|
ASX - By Stock
|
MSB |
Re:
2023 The Final Countdown
|
|
mtom
|
3.4K |
1.1M |
4 |
26/07/23 |
26/07/23 |
ASX - By Stock
|
3.4K
|
1.1M
|
4
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MESO watch and banter
|
|
mtom
|
400 |
147K |
5 |
24/07/23 |
24/07/23 |
ASX - By Stock
|
400
|
147K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
2023 The Final Countdown
|
|
mtom
|
3.4K |
1.1M |
7 |
13/07/23 |
13/07/23 |
ASX - By Stock
|
3.4K
|
1.1M
|
7
|
|
ASX - By Stock
|
MSB |
Re:
MSB $2 Party.
|
|
mtom
|
125 |
55K |
10 |
11/07/23 |
11/07/23 |
ASX - By Stock
|
125
|
55K
|
10
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
mtom
|
4.8K |
2.3M |
7 |
20/06/23 |
20/06/23 |
ASX - By Stock
|
4.8K
|
2.3M
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: MSB Reports Q3 Financial Results and Operational Highlights
|
|
mtom
|
362 |
111K |
10 |
26/05/23 |
26/05/23 |
ASX - By Stock
|
362
|
111K
|
10
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
mtom
|
4.8K |
2.3M |
5 |
24/05/23 |
24/05/23 |
ASX - By Stock
|
4.8K
|
2.3M
|
5
|
|
ASX - By Stock
|
MSB |
Re:
MSB $1 Party
|
|
mtom
|
1.1K |
317K |
4 |
10/05/23 |
10/05/23 |
ASX - By Stock
|
1.1K
|
317K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
MSB $1 Party
|
|
mtom
|
1.1K |
317K |
7 |
10/05/23 |
10/05/23 |
ASX - By Stock
|
1.1K
|
317K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
mtom
|
274 |
119K |
9 |
20/04/23 |
20/04/23 |
ASX - By Stock
|
274
|
119K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Huge uplift predicted for Mesoblast
|
|
mtom
|
82 |
28K |
13 |
28/03/23 |
28/03/23 |
ASX - By Stock
|
82
|
28K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
mtom
|
13K |
4.9M |
16 |
13/03/23 |
13/03/23 |
ASX - By Stock
|
13K
|
4.9M
|
16
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
mtom
|
9.3K |
2.6M |
5 |
03/03/23 |
03/03/23 |
ASX - By Stock
|
9.3K
|
2.6M
|
5
|
|
ASX - By Stock
|
CSL |
Re:
Fair Value
|
|
mtom
|
117 |
56K |
6 |
03/02/23 |
03/02/23 |
ASX - By Stock
|
117
|
56K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Rexlemestrocel-L Improves LVEF, Preceding Reduction in MACE
|
|
mtom
|
299 |
103K |
6 |
14/12/22 |
14/12/22 |
ASX - By Stock
|
299
|
103K
|
6
|
|
ASX - By Stock
|
CYP |
Re:
Going forward...
|
|
mtom
|
2.1K |
667K |
6 |
13/12/22 |
13/12/22 |
ASX - By Stock
|
2.1K
|
667K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
mtom
|
9.3K |
2.6M |
16 |
05/12/22 |
05/12/22 |
ASX - By Stock
|
9.3K
|
2.6M
|
16
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2022, The TurnAround
|
|
mtom
|
1.0K |
319K |
8 |
30/11/22 |
30/11/22 |
ASX - By Stock
|
1.0K
|
319K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
mtom
|
67 |
22K |
11 |
31/10/22 |
31/10/22 |
ASX - By Stock
|
67
|
22K
|
11
|
|
Charts
|
MSB |
Re:
MSB - Chart
|
|
mtom
|
248 |
103K |
9 |
10/10/22 |
10/10/22 |
Charts
|
248
|
103K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
15 Days until doubt is removed
|
|
mtom
|
953 |
288K |
6 |
29/09/22 |
29/09/22 |
ASX - By Stock
|
953
|
288K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
mtom
|
9.3K |
2.6M |
3 |
21/09/22 |
21/09/22 |
ASX - By Stock
|
9.3K
|
2.6M
|
3
|
|
ASX - By Stock
|
MSB |
Re:
MSB $1 Party
|
|
mtom
|
1.1K |
317K |
12 |
21/07/22 |
21/07/22 |
ASX - By Stock
|
1.1K
|
317K
|
12
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
mtom
|
9.3K |
2.6M |
4 |
28/06/22 |
28/06/22 |
ASX - By Stock
|
9.3K
|
2.6M
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
mtom
|
17K |
6.5M |
5 |
29/03/22 |
29/03/22 |
ASX - By Stock
|
17K
|
6.5M
|
5
|
|
ASX - By Stock
|
MSB |
Re:
2022 ... Get your popcorn out!
|
|
mtom
|
778 |
278K |
8 |
26/03/22 |
26/03/22 |
ASX - By Stock
|
778
|
278K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Director Appointment
|
|
mtom
|
213 |
58K |
8 |
24/03/22 |
24/03/22 |
ASX - By Stock
|
213
|
58K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Director Appointment
|
|
mtom
|
213 |
58K |
37 |
24/03/22 |
24/03/22 |
ASX - By Stock
|
213
|
58K
|
37
|
|
ASX - By Stock
|
MSB |
Re:
MESOBLAST- FUNDAMENTALS discussions
|
|
mtom
|
305 |
113K |
3 |
01/03/22 |
01/03/22 |
ASX - By Stock
|
305
|
113K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: 36-Month Results of Phase 3 Trial in Chronic Low Back Pain
|
|
mtom
|
373 |
86K |
6 |
12/01/22 |
12/01/22 |
ASX - By Stock
|
373
|
86K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
A Lesson from Osiris
|
|
mtom
|
66 |
20K |
5 |
24/12/21 |
24/12/21 |
ASX - By Stock
|
66
|
20K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDAs OTAT Agrees to Primary Endpoint for Back Pain
|
|
mtom
|
408 |
122K |
4 |
17/12/21 |
17/12/21 |
ASX - By Stock
|
408
|
122K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDAs OTAT Agrees to Primary Endpoint for Back Pain
|
|
mtom
|
408 |
122K |
16 |
16/12/21 |
16/12/21 |
ASX - By Stock
|
408
|
122K
|
16
|
|
ASX - By Stock
|
MSB |
Re:
Novartis countdown
|
|
mtom
|
373 |
111K |
5 |
26/11/21 |
26/11/21 |
ASX - By Stock
|
373
|
111K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: MSB and Oaktree Conclude Refinancing of Senior Debt Facility
|
|
mtom
|
451 |
113K |
15 |
22/11/21 |
22/11/21 |
ASX - By Stock
|
451
|
113K
|
15
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
mtom
|
10K |
3.0M |
5 |
22/11/21 |
22/11/21 |
ASX - By Stock
|
10K
|
3.0M
|
5
|
|
ASX - By Stock
|
MSB |
Re:
the shorts will bail with margin calling and announcements due
|
|
mtom
|
482 |
119K |
9 |
03/11/21 |
03/11/21 |
ASX - By Stock
|
482
|
119K
|
9
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
mtom
|
10K |
3.0M |
7 |
05/10/21 |
05/10/21 |
ASX - By Stock
|
10K
|
3.0M
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Rem-L Needed NOW
|
|
mtom
|
179 |
48K |
5 |
24/09/21 |
24/09/21 |
ASX - By Stock
|
179
|
48K
|
5
|
|
ASX - By Stock
|
MSB Biotech |
Re:
NSW COVID FORECAST
|
|
mtom
|
40 |
10K |
4 |
08/09/21 |
08/09/21 |
ASX - By Stock
|
40
|
10K
|
4
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
mtom
|
10K |
3.0M |
20 |
02/08/21 |
02/08/21 |
ASX - By Stock
|
10K
|
3.0M
|
20
|
|
ASX - By Stock
|
MSB |
Re:
Risk management
|
|
mtom
|
95 |
23K |
3 |
04/06/21 |
04/06/21 |
ASX - By Stock
|
95
|
23K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
RYONCIL GvHD Trial
|
|
mtom
|
7 |
2.0K |
4 |
19/05/21 |
19/05/21 |
ASX - By Stock
|
7
|
2.0K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast in Freefall
|
|
mtom
|
982 |
280K |
4 |
14/05/21 |
14/05/21 |
ASX - By Stock
|
982
|
280K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: COVID ARDS Trial Topline 60-Day Results
|
|
mtom
|
1.6K |
459K |
2 |
13/05/21 |
13/05/21 |
ASX - By Stock
|
1.6K
|
459K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast in Freefall
|
|
mtom
|
982 |
280K |
1 |
13/05/21 |
13/05/21 |
ASX - By Stock
|
982
|
280K
|
1
|
|